At the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Fund’s Scientific Advisory Board, about the construction and the goal of the fund.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb2018springaleksengel.jpg450800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-15 12:37:482024-04-02 16:21:28Making an impact on AMR R&D
Researchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-15 07:26:432018-03-15 07:26:43Algorithm tracks cancer type down to methylation pattern
The tremendous success of last year’s BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.
https://european-biotechnology.com/wp-content/uploads/2024/04/2018_03_14_BIOEuropeSpring.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-14 08:39:272018-03-14 08:39:27Business as usual in Amsterdam
Domainex Ltd, a privately-owned drug discovery services company, has announced the appointment of Dr Bodo Spori as Head of Business Development for Europ.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bodo_Spori_small.jpg400400Michael Kuhrt/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMichael Kuhrt2018-03-13 11:39:182018-03-13 11:39:18Domainex appoints Dr Bodo Spori
German MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agency’s PRIME scheme.
SP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired.
https://european-biotechnology.com/wp-content/uploads/2024/04/brianlarkin_small.png400400Michael Kuhrt/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMichael Kuhrt2018-03-12 11:29:002018-03-12 11:29:00SP Industries Announces Brian Larkin as President and CEO
Alirocumab, Sanofi’ s/Regeneron’s PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
About 300 bioeconomy experts from science and business came together in Strasbourg for the first edition of BIOKET to discuss up-scaling challenges, new processing technologies as well as the potential of synthetic biology and digitalization.
https://european-biotechnology.com/wp-content/uploads/2024/04/2018_1103_partnering_bioket_web.jpg5631001Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-09 06:57:002018-03-09 06:57:00Bioprocessing challenges in the focus
The adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Winter_2017_miraculousmicrobiome.jpg12002000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-08 15:00:002024-04-02 16:21:29Learning to listen to your gut
Making an impact on AMR R&D
BackgroundAt the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Fund’s Scientific Advisory Board, about the construction and the goal of the fund.
Algorithm tracks cancer type down to methylation pattern
Latest NewsResearchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.
Business as usual in Amsterdam
Latest NewsThe tremendous success of last year’s BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.
Domainex appoints Dr Bodo Spori
AppointmentsMYR Pharma completes chronic hepatitis delta POC trial
Latest NewsGerman MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agency’s PRIME scheme.
SP Industries Announces Brian Larkin as President and CEO
AppointmentsSP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired.
Sanofi’s alirocumab improves cardiovascular event rate over statins
Latest NewsAlirocumab, Sanofi’ s/Regeneron’s PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Medimmune finds target against systemic sclerosis
Latest NewsResearchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis.
Bioprocessing challenges in the focus
Latest NewsLearning to listen to your gut
BackgroundThe adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.